Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Sun Pharmaceuticals Industries Ltd Performance

Today's Low
1,505.55
arrowIcon
Today's High
1,518.00
52 Wk Low
977.30
arrowIcon
52 Wk High
1,638.85


Open

1513.85

Traded Value (Cr)

142.12

Prev. Close

1516

Face Value

1

Volume

937490

Sun Pharmaceuticals Industries Ltd Fundamentals

Market Cap
₹ 363691.19 Cr
P/E Ratio (TTM)
36.34
P/B Ratio
5.71
Debt to Equity
0.08
ROE
13.89
EPS (TTM)
41.71
Dividend Yield
0.89 %
Book Value
265.35

Click here to know more about Fundamentals

Sun Pharmaceuticals Industries Ltd F&O

Sun Pharmaceuticals Industries Ltd Option Chain

Sun Pharmaceuticals Industries Ltd Financials

Sun Pharmaceuticals Industries Ltd Financials

Sun Pharmaceuticals Industries Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 54.48 % 54.48 % 54.48 % 54.48 %
FII 17.72 % 17.07 % 16.79 % 16.48 %
Mutual Funds 12.21 % 12.93 % 13.07 % 13.16 %
Others 10.15 % 10.11 % 10.10 % 10.23 %
Retail 5.44 % 5.41 % 5.56 % 5.65 %

Promoters

54.48%

FII

17.72%

Mutual Funds

12.21%

Others

10.15%

Retail

5.44%

Promoters

54.48%

FII

17.07%

Mutual Funds

12.93%

Others

10.11%

Retail

5.41%

Promoters

54.48%

FII

16.79%

Mutual Funds

13.07%

Others

10.10%

Retail

5.56%

Promoters

54.48%

FII

16.48%

Mutual Funds

13.16%

Others

10.23%

Retail

5.65%

Resistance and Support

₹1,513.18

PIVOT

resistance-arrow
Resistance
First Resistance₹1,520.817
Second Resistance₹1,525.633
Third Resistance₹1,533.267
support-arrow
Support
First Support₹1,508.367
Second Support₹1,500.733
Third Support₹1,495.917

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day1,412,477505,31253.90
Week937,490715,487-39.36
1 Month937,4901,525,721-39.36
6 Months310,040,652193,226,77861.11

About Sun Pharmaceuticals Industries Ltd

Company Overview

Sun Pharmaceutical Industries Ltd. (Sun Pharma), which generates global sales of more than US$ 5.1 billion, is the fourth-largest specialty generic pharmaceutical firm in the world. With the help of more than 40 production facilities, we supply more than 100 nations with high-quality, reasonably priced medications that are dependable among patients and medical experts.

Sun Pharmaceutical Industries Ltd - History and Expansion

In Vapi, Gujarat, Dilip Shanghvi founded Sun Pharmaceuticals in 1983 with five mental drug products. Cardiology and gastrointestinal products first became available in 1987 and 1989, respectively. Currently, it is India's top-selling prescription drug and a market leader in cardiology, gastroenterology, orthopedics, diabetology, dermatology, urology, vitamins, minerals, and nutrients.

Sun Pharma became the biggest pharmaceutical firm in India, the biggest Indian pharmaceutical business in the US, and the fourth-largest specialty generic company in the world after purchasing Ranbaxy in 2014.

The United States and other markets outside of India account for more than 72% of Sun Pharma's sales. The US is the company's single-largest market, contributing around 30% of total sales, with formulations or final dosage forms accounting for 93% of sales. 44 locations worldwide, including those in Europe, Asia, Africa, Australia, and the US, are used for manufacturing. The firm sells a wide range of generic medications in the US, and it has a healthy pipeline of products awaiting FDA clearance.

In 1994, Sun Pharma went public on the stock market in a 55-fold oversubscribed offering. The company's majority ownership remains with the original family.

IPO of Sun Pharmaceutical Industries Ltd

It was 1994 when Sun Pharma went public. To generate money and become a publicly listed corporation, a firm must first offer its shares to the general public. This is known as an IPO. Investors were able to become shareholders in Sun Pharma by purchasing shares of the business at the 1994 IPO. It was priced at Rs 150 to issue, and it was listed for about Rs 220. The stock price dropped from its listing price within a month of the IPO, by roughly 20%.

About Company

Sun Pharmaceutical Industries Ltd., is a large-cap company in the pharmaceuticals sector with a market capitalization of Rs. 259,572.05 billion. Pharmaceuticals and Other Operating Revenue are among Sun Pharmaceutical Industries Ltd.'s primary product/revenue segments for the fiscal year ending March 31, 2022.

Consolidated Total Income for the three months ending March 31, 2023, was Rs 11,303.95 crore, down 97% from the previous quarter's total income of Rs 11,414.85 crore and up 18.24% from the same period last year's total income of Rs 9,560.35 crore. In the most recent quarter, the company generated a net profit after tax of Rs 2,016.78 billion.

The top executives of the firm include Mr. Israel Makov, Mr. Dilip S. Shanghvi, Dr. Uday Baldota, Mr. Abhay Gandhi, Mr. Kirti Ganorkar, Mr. Kalyanasundaram Subramanian, Mr. Sailesh T. Desai, Dr. Pawan Goenka, Mr. Rama Bijapurkar, Mr. Sudhir V. Valia, Mr. Gautam Doshi, Mr. C. S. The company's auditors are S R B C & Co. LLP. As of March 31, 2023, the corporation has 239.93 billion shares outstanding.

Group companies

Ranbaxy Laboratories Limited (2014): Sun Pharmaceutical purchased Ranbaxy Laboratories Limited, a renowned Indian pharmaceutical business, in 2014, in one of the most important acquisitions in the pharmaceutical sector. Sun Pharma was able to dramatically increase its market share and product portfolio thanks to the $3.2 billion transaction.

AstraZeneca (2016): To develop and market certain products in China, Sun Pharmaceutical and the international pharmaceutical giant AstraZeneca established a joint venture in 2016. The partnership made use of AstraZeneca's global reach and Sun Pharma's manufacturing capabilities.

Pola Pharma Inc. (2021): Sun Pharmaceutical stated in January 2021 that it has agreed to buy the Japanese pharmaceutical firm Pola Pharma Inc. for about JPY 2,800 million. Sun Pharma's position in the Japanese pharmaceutical industry was to be strengthened by this tactical action.

Sun Pharmaceutical Industries Ltd Share Price

The share price of Sun Pharmaceutical Industries Ltd. is a crucial sign of how investors feel about the business. Several variables, including the company's financial performance, the state of the global economy, and market sentiment, have an impact on the share price. Over the past several years, Sun Pharmaceutical Industries Ltd.'s share price has been on the rise, indicating the company's solid financial performance and growth potential. You can check the live price of Sun Pharmaceutical Industries Ltd from the above part.

Managing Director

Dilip S Shanghvi

Founded

1993

NSE Symbol

SUNPHARMA

Sun Pharmaceuticals Industries Ltd Management

NameDesignation
Dilip S ShanghviManaging Director
Sudhir V ValiaNon-Exec & Non-Independent Dir
Sailesh T DesaiWhole-time Director
Gautam DoshiNon-Exec. & Independent Dir.
Pawan GoenkaLead Independent Director
Rama BijapurkarIndependent Director
Anoop DeshpandeCompany Sec. & Compli. Officer
Sanjay K AsherIndependent Director
Rolf HoffmannIndependent Director
Aalok ShanghviWhole Time Director

Sun Pharmaceuticals Industries Ltd News

Taro shareholders approve merger with Sun Pharma
Board of Sun Pharmaceuticals Industries recommends final dividend
Of Rs 5 per share
Sun Pharma Q4 PAT rises 34% YoY to Rs 2,656 cr
The pharma major’s consolidated net profit jumped 33.77% to Rs 2,654.58 crore in Q4 FY24 as against Rs 1,984.47 crore posted in Q4 FY23.
Sun Pharmaceuticals Industries consolidated net profit rises 33.77% in the March 2024 quarter
Sales rise 10.14% to Rs 11813.33 crore
Sun Pharmaceuticals appoints Dilip Shanghvi as Chairman
With immediate effect
Stock alert: Sun Pharma, PayTM, Nykaa, Reliance Industries, P I Inds
Sun Pharmaceuticals Industries to hold board meeting
On 22 May 2024
Sun Pharmaceuticals Industries Ltd slips for fifth straight session
Sun Pharmaceuticals Industries Ltd is quoting at Rs 1602.95, down 0.38% on the day as on 13:19 IST on the NSE. The stock jumped 58.93% in last one year as compared to a 28.75% rally in NIFTY and a 56.37% spurt in the Nifty Pharma index.
Sun Pharmaceuticals Industries Ltd spurts 2.46%, rises for third straight session
Sun Pharmaceuticals Industries Ltd is quoting at Rs 1603.7, up 2.46% on the day as on 12:49 IST on the NSE. The stock is up 64.04% in last one year as compared to a 29.37% gain in NIFTY and a 59.35% gain in the Nifty Pharma index.
Sun Pharma receives nod to launch Winlevi® in Australia

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Cipla Ltd₹ 126345.07 Cr
₹ 1,564.75
(1.31 %)
34.03
Divis Laboratories Ltd₹ 121812.91 Cr
₹ 4,588.60
(-0.11 %)
77.26
Zydus Lifesciences Ltd₹ 111646.69 Cr
₹ 1,109.55
(1.75 %)
32.35
Dr Reddys Laboratories Ltd₹ 101516.8 Cr
₹ 6,085.25
(-0.17 %)
23.38
Torrent Pharmaceuticals Ltd₹ 97538.98 Cr
₹ 2,882.10
(0.25 %)
71.88

Sun Pharmaceuticals Industries Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Sun Pharmaceuticals Industries Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Sun Pharmaceuticals Industries Ltd's share price is ₹1,516.00 as of June 14, 2024 at 04:14 PM

Sun Pharmaceuticals Industries Ltd's P/E ratio is 36.34 times as of June 14, 2024 at 04:14 PM.

Sun Pharmaceuticals Industries Ltd's most recent financial reports indicate a price-to-book ratio of 5.71, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Sun Pharmaceuticals Industries Ltd's market is 363,691 Cr as on June 14, 2024 at 04:14 PM.

The current financial records of Sun Pharmaceuticals Industries Ltd show a 13.89% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Sun Pharmaceuticals Industries Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

The 52-week high/low price of a Sun Pharmaceuticals Industries Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Sun Pharmaceuticals Industries Ltd's 52-week high and low as of June 14, 2024 at 04:14 PM are ₹1638.85 and ₹977.3 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Sun Pharmaceuticals Industries Ltd stands at 54.48%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 17.07% to 17.72%.